Horizon Pharma Inc. (NASDAQ:HZNP) has been assigned a $26.00 price objective by analysts at Goldman Sachs Group Inc. in a research report issued to clients and investors on Wednesday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price target points to a potential upside of 47.14% from the stock’s current price.
Several other analysts have also weighed in on the stock. Guggenheim reaffirmed a “buy” rating and set a $30.00 price objective on shares of Horizon Pharma in a report on Tuesday, August 23rd. Cowen and Company reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Horizon Pharma in a report on Monday, September 12th. Vetr raised shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating in a report on Monday, October 3rd. Mizuho raised their price objective on shares of Horizon Pharma from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, September 13th. Finally, Morgan Stanley reaffirmed a “hold” rating and set a $24.00 price objective on shares of Horizon Pharma in a report on Wednesday, September 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Horizon Pharma presently has an average rating of “Buy” and an average price target of $29.92.
Shares of Horizon Pharma (NASDAQ:HZNP) traded up 2.55% during midday trading on Wednesday, hitting $18.12. The stock had a trading volume of 2,015,114 shares. Horizon Pharma has a 52 week low of $12.86 and a 52 week high of $23.70. The stock has a 50-day moving average of $18.79 and a 200 day moving average of $17.86. The stock’s market cap is $2.92 billion.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The firm earned $257.40 million during the quarter, compared to analysts’ expectations of $235.43 million. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The company’s revenue for the quarter was up 48.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.39 earnings per share. Analysts anticipate that Horizon Pharma will post $2.15 EPS for the current fiscal year.
In related news, EVP Jeffrey W. Sherman sold 2,900 shares of the business’s stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total value of $58,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.10% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in Horizon Pharma by 1.7% in the second quarter. FMR LLC now owns 23,353,416 shares of the biopharmaceutical company’s stock valued at $384,631,000 after buying an additional 401,302 shares in the last quarter. Deerfield Management Co. boosted its stake in Horizon Pharma by 17.6% in the first quarter. Deerfield Management Co. now owns 13,740,261 shares of the biopharmaceutical company’s stock valued at $227,676,000 after buying an additional 2,055,460 shares in the last quarter. Vanguard Group Inc. boosted its stake in Horizon Pharma by 7.5% in the second quarter. Vanguard Group Inc. now owns 10,569,177 shares of the biopharmaceutical company’s stock valued at $174,074,000 after buying an additional 737,812 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Horizon Pharma by 127.3% in the second quarter. BlackRock Fund Advisors now owns 6,678,136 shares of the biopharmaceutical company’s stock valued at $109,989,000 after buying an additional 3,740,449 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Horizon Pharma by 28.6% in the second quarter. JPMorgan Chase & Co. now owns 4,341,698 shares of the biopharmaceutical company’s stock valued at $71,508,000 after buying an additional 964,505 shares in the last quarter. 85.25% of the stock is currently owned by institutional investors and hedge funds.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.